290.67

0.23% 2.8299

Bio Rad Laboratories Inc (BIO)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Bio Rad Laboratories Inc stock is traded at $290.67, with a volume of 12,088. It is up +0.23% in the last 24 hours and up +8.70% over the past month. Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Previous Close:

$287.84

Open:

$287.8

24h Volume:

12,088

Relative Volume:

0.04

Market Cap:

$7.85B

Revenue:

$2.58B

Net Income/Loss:

$759.90M

P/E Ratio:

10.41

EPS:

27.9168

Net Cash Flow:

$374.60M

1W Performance:

-4.89%

1M Performance:

+8.70%

6M Performance:

-14.17%

1Y Performance:

+18.91%

1-Day Range:

$284.65

$294.05

1-Week Range:

$274.89

$312.85

52-Week Range:

$211.43

$343.12

Bio Rad Laboratories Inc Stock (BIO) Company Profile

Name

Bio Rad Laboratories Inc

Sector

Healthcare (1108)

Industry

Medical Devices (142)

Phone

(510) 724-7000

Address

1000 ALFRED NOBEL DRIVE, HERCULES

Employee

7,450

Twitter

@BioRadLifeSci

Next Earnings Date

2026-04-30

Latest SEC Filings

BIO's Discussions on Twitter

Compare BIO vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BIO Bio Rad Laboratories Inc	290.90	7.77B	2.58B	759.90M	374.60M	27.92
ABT Abbott Laboratories	92.98	158.35B	45.13B	6.28B	7.40B	3.5895
SYK Stryker Corp	330.72	125.43B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	83.94	106.97B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	61.22	92.25B	20.62B	3.56B	3.66B	2.3847
EW Edwards Lifesciences Corp	84.32	48.52B	6.30B	1.07B	1.34B	1.8406

Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-07-26	Downgrade	Citigroup	Buy → Neutral
Oct-01-24	Upgrade	Citigroup	Neutral → Buy
Aug-28-24	Initiated	Wells Fargo	Equal Weight
Jun-03-24	Resumed	Jefferies	Hold
Apr-03-24	Downgrade	Citigroup	Buy → Neutral
Dec-07-23	Initiated	UBS	Buy
Jun-16-23	Initiated	Wells Fargo	Overweight
Dec-07-22	Initiated	RBC Capital Mkts	Outperform
Aug-25-22	Initiated	Credit Suisse	Outperform
Jan-28-22	Reiterated	Citigroup	Buy
Jan-08-20	Initiated	Wells Fargo	Overweight
Jan-07-20	Initiated	Citigroup	Buy
Oct-17-18	Initiated	Goldman	Buy
Sep-20-18	Initiated	Morgan Stanley	Equal-Weight
Feb-16-18	Downgrade	CL King	Buy → Neutral
Jul-13-17	Initiated	Wells Fargo	Outperform
Jun-28-17	Upgrade	Deutsche Bank	Hold → Buy
Jan-18-17	Initiated	Deutsche Bank	Hold
Oct-13-16	Initiated	CL King	Buy
May-06-15	Reiterated	Jefferies	Buy
Dec-18-09	Initiated	Maxim Group	Buy
Nov-06-09	Initiated	Jefferies & Co	Buy
Jul-17-09	Initiated	Soleil	Buy
Sep-26-07	Initiated	Banc of America Sec	Buy
Feb-23-07	Downgrade	Robert W. Baird	Outperform → Neutral

View All

Bio Rad Laboratories Inc Stock (BIO) Latest News

12:31 PM

Citigroup downgrades Bio-Rad Laboratories (BIO) - MSN

12:31 PM

Apr 25, 2026

Bio-Rad Laboratories, Inc. Amends 2017 Incentive Award Plan and Updates Entity Information in April 2026 8-K Filing - Minichart

Apr 25, 2026

Apr 24, 2026

Bio-Rad Laboratories Stockholders Approve Directors and Governance Items - TipRanks

Apr 24, 2026

Shareholders of Bio-Rad (NYSE: BIO) approve 2017 incentive plan changes - Stock Titan

Apr 24, 2026